Company research
Rezolute, Inc.
CIK 1509261Updated Sep 27, 2026
SecurityRZLT · NASDAQ · equity
Name history
AntriaBio, Inc. · through Dec 7, 2017FITS MY STYLE INC · through Jan 11, 2013
RZLT price & chart
Loading TradingView…
NASDAQ:RZLT on TradingView ↗About the company
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
In the news
Rezolute to Participate in Upcoming Investor Conferences ↗
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT) ↗
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute News provided by Faruqi & Faruqi, LLP Jan 29, 2026, 08:35 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wil ↗
Recent filings
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 112,849,000Source | 175,490,000Source | 132,737,000Source | 123,721,000Source |
| Property, Plant and Equipment, NetUSD | 41,000Source | 72,000Source | 103,000Source | 139,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,615,000Source | 94,107,000Source | 70,396,000Source | 16,036,000Source |
| Assets, CurrentUSD | 110,511,000Source | 171,145,000Source | 128,653,000Source | 104,910,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,710,000Source | 3,287,000Source | 1,779,000Source | 3,014,000Source |
| Operating Lease, Right-of-Use AssetUSD | 769,000Source | 1,348,000Source | 1,880,000Source | 2,054,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,162,000Source | 13,363,000Source | 11,734,000Source | 7,549,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 96,000Source | 87,000Source | 53,000Source | 37,000Source |
| Additional Paid in CapitalUSD | 582,152,000Source | 565,903,000Source | 450,473,000Source | 377,471,000Source |
| Retained Earnings (Accumulated Deficit)USD | -481,442,000Source | -403,856,000Source | -329,444,000Source | -260,985,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -119,000Source | -7,000Source | -79,000Source | -351,000Source |
| Stockholders' Equity Attributable to ParentUSD | 100,687,000Source | 162,127,000Source | 121,003,000Source | 116,172,000Source |
| Liabilities and EquityUSD | 112,849,000Source | 175,490,000Source | 132,737,000Source | 123,721,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,418,000Source | 11,912,000Source | 9,606,000Source | 5,200,000Source |
| Operating Lease, Liability, CurrentUSD | 658,000Source | 632,000Source | 568,000Source | 541,000Source |
| Accounts Payable, CurrentUSD | 5,026,000Source | 5,809,000Source | 4,901,000Source | 3,269,000Source |
| Operating Lease, Liability, NoncurrentUSD | 276,000Source | 983,000Source | 1,660,000Source | 1,937,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,460,000Source | 7,121,000Source | 7,360,000Source | 7,268,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -748,000Source | 1,421,000Source | 1,083,000Source | 2,136,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -64,635,000Source | -69,075,000Source | -57,368,000Source | -44,481,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -21,098,000Source | -14,541,000Source | 48,699,000Source | -101,464,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 153,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 3,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,241,000Source | 107,327,000Source | 63,029,000Source | 11,571,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -83,492,000Source | 23,711,000Source | 54,360,000Source | -134,374,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,615,000Source | 94,107,000Source | 70,396,000Source | 16,036,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,460,000Source | 7,121,000Source | 7,360,000Source | 7,268,000Source |
| DepreciationUSD | 31,000Source | 31,000Source | 36,000Source | 30,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | 29,168,000Source | 18,367,000Source | 14,680,000Source | 12,177,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Nonoperating Income (Expense)USD | — | 5,482,000Source | 1,964,000Source | 4,203,000Source |
| Operating ExpensesUSD | 82,966,000Source | 79,894,000Source | 70,423,000Source | 55,990,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 607,000Source |
| Proceeds from Stock Options ExercisedUSD | 2,276,000Source | 893,000Source | 234,000Source | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -82,966,000Source | -79,894,000Source | -70,423,000Source | -55,990,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Earnings Per Share, BasicUSD per share | -0.75Source | -0.98Source | -1.33Source | -1.01Source |
| Earnings Per Share, DilutedUSD per share | -0.75Source | -0.98Source | -1.33Source | -1.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 103,907,114Source | 75,999,290Source | 51,465,000Source | 51,187,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 103,907,114Source | 75,999,290Source | 51,465,000Source | 51,187,000Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 31,000Source | 31,000Source | 36,000Source | 30,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | 29,168,000Source | 18,367,000Source | 14,680,000Source | 12,177,000Source |
| Interest and Other IncomeUSD | 5,380,000Source | 5,482,000Source | 4,870,000Source | 4,208,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -77,586,000Source | -74,412,000Source | -68,459,000Source | -51,787,000Source |
| Nonoperating Income (Expense)USD | — | 5,482,000Source | 1,964,000Source | 4,203,000Source |
| Operating ExpensesUSD | 82,966,000Source | 79,894,000Source | 70,423,000Source | 55,990,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 607,000Source |
| Research and Development ExpenseUSD | 53,798,000Source | 61,527,000Source | 55,743,000Source | 43,813,000Source |
Filing attachments
rzlt-20260630xex4d1.htm · 10-K · 2026-09-24
EXHIBIT 4.1 DESCRIPTION OF SECURITIES General The following description summarizes the most important terms of our capital stock. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation, as amended (“Articles of Incorporation”) and Amended and Restated Bylaws (“Bylaws”), which are included as exhibits to our annual report on Form 10-K, of which this Exhibit 4.1 is a part. We encourage you to read our Articles of Incorporation, our Byla…
Read attachment ↗tm2625842d1_ex99-1.htm · 8-K · 2026-09-24
Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., September 24, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HI u…
Read attachment ↗tm2616579d1_ex99-1.htm · 8-K · 2026-06-02
EX-99.1 2 tm2616579d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 REDWOOD CITY, Calif., June 2, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage…
Read attachment ↗tm2614169d1_ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 tm2614169d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., May 12, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026. Congenital Hyperinsulinism …
Read attachment ↗tm2613408d1_ex99-1.htm · 8-K · 2026-05-04
EX-99.1 2 tm2613408d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post…
Read attachment ↗tm269642d1_ex99-1.htm · 8-K · 2026-03-24
EX-99.1 2 tm269642d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulini…
Read attachment ↗